Tranexamic Acid for The Treatment of Gastrointestinal Bleeding
Tranexamic Acid for The Treatment of Gastrointestinal Bleeding
Studies showed that in cases of gastrointestinal bleeding, injection tranexamic acid
 decreasing the risk of death and the need of surgical intervention. However, the quality of
 most clinical trials were not good and the results were not significant. Injection tranexamic
 acid does not become one of the treatment option in the international guidelines nor in
 national consensus, so the effectiveness and the safety of its use in the treatment of
 gastrointestinal bleeding remains unclear and not routinely used.

 In Indonesia, injection tranexamic acid in gastrointestinal bleeding is limitedly used and
 recorded. Therefore, a clinical trial study of injection tranexamic acid is required to
 assess the effectiveness and the safety in the treatment of gastrointestinal bleeding.
This study is a randomized double-blind controlled trial study. Interventions were given in
 the form of tranexamic acid injection compared to placebo in patients with acute upper and
 lower gastrointestinal bleeding. Tranexamic acid were administered intravenously 1 gram
 loading dose, followed by 3 grams maintenance dose in infusion for 24 hours. Other routine
 and standardized drugs for gastrointestinal bleeding will still be given. Statistical
 analysis will use: Chi square test or Kolmogorov-Smirnov with alternative Fisher test for
 categorical dependent-variable; Independent T-Test with alternative Mann-Whitney test for
 two-group numerical dependent-variable; and one-way ANOVA with alternative Kruskal-Wallis for
 more than two-groups numerical dependent-variable.
Inclusion Criteria:

 -  Adults

 -  Patients with acute lower and upper gastrointestinal bleeding (assessed clinically)

 -  Patients agreed to participate in the study and signed the informed consent

 Exclusion Criteria:

 -  Allergy with tranexamic acid

 -  Patients considered by the clinician can not be randomized to participate in the study

 -  Patients with chronic kidney disease stage III - V